Trial0
Sign inMap the options

Clinical trial · NCT06885034 · RECRUITING · PHASE1 / PHASE2

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)

Sponsor: GlaxoSmithKline

Request access helpRegistry record ↗

We save this real registry record and notify you if its published status changes. Create an account to add profile details that improve future matching.

Summary

This study will check how well a new medicine, Risvutatug rezetecan, (Ris-Rez, also known as GSK5764227) works, how safe it is and how the body handles it in participants all around the world with advanced inoperable or metastatic gastrointestinal cancer who have previously received treatment.

Interventions

  • Risvutatug Rezetecan · BIOLOGICAL

    Risvutatug Rezetecan will be administered

  • Drug 1 · DRUG

    Drug 1 will be administered

  • Drug 2 · DRUG

    Drug 2 will be administered

  • Drug 3 · DRUG

    Drug 3 will be administered

  • Drug 4 · DRUG

    Drug 4 will be administered

Published eligibility criteria

Verbatim from the registry. Only the site can decide how these apply to a specific patient.

Inclusion criteria:

Participants are eligible to be included in the study only if all of the following criteria apply:

* Is at least 18 or the legal age of consent in the jurisdiction in which the study is taking place years of age at the time of signing the informed consent form (ICF).

CRC Cohort

* Has histologically confirmed unresectable, locally advanced or unresectable metastatic adenocarcinoma of the colon or rectum (histology defined by World Health Organization (WHO) classification).

PDAC Cohort

* Has histologically or cytologically confirmed unresectable, locally advanced or metastatic adenocarcinoma of the pancreas (histology defined by WHO classification).

All Cohorts

* Is willing to use adequate contraception.
* Is capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the ICF and in the protocol.
* Has an ECOG performance status of 0 or 1.
* Has adequate organ function.

Exclusion criteria:

Participants are excluded from the study if any of the following criteria apply:

* Has a malignancy (except disease under study) that has progressed or required active treatment within the past 24 months except for basal cell or squamous cell carcinomas of the skin or in-situ carcinomas \[e.g., breast, cervix, bladder\] that have been resected with no evidence of disease.
* Has had any major surgery within 28 days prior to randomization or first dose of study intervention, depending on sub-cohort/cohort assignment
* Has any history of prior allogenic or autologous bone marrow transplant or other solid organ transplant.
* Has severe, uncontrolled or active cardiovascular disorders.
* Has serious or poorly controlled hypertension.
* Has clinically significant bleeding symptoms or significant bleeding tendency within 1 month prior to the first dose.
* Has untreated brain or Central nervous system (CNS) metastases or brain/CNS metastases that have progressed.
* Has evidence of current ILD/non-infectious pneumonitis or a prior history of ILD/non-infectious pneumonitis requiring high-dose glucocorticoids Or suspected ILD/non-infectious pneumonitis that cannot be ruled out by imaging.
* Has ongoing adverse reaction(s) from prior therapy that has(have) not recovered to Grade 1 or to the baseline status preceding prior therapy.
* Has received any prior therapy with an Antibody-drug conjugate (ADC) with a Topoisomerase-1 (TOPO1)-inhibitor payload.
* Is pregnant or breastfeeding.

Sites (85)

  • GSK Investigational Site, Los Alamitos, California · RECRUITING
  • GSK Investigational Site, Los Angeles, California · RECRUITING
  • GSK Investigational Site, Santa Monica, California · RECRUITING
  • GSK Investigational Site, Whittier, California · RECRUITING
  • GSK Investigational Site, Aurora, Colorado · RECRUITING
  • GSK Investigational Site, New York, New York · RECRUITING
  • GSK Investigational Site, New York, New York · RECRUITING
  • GSK Investigational Site, Durham, North Carolina · RECRUITING
  • GSK Investigational Site, Houston, Texas · RECRUITING
  • GSK Investigational Site, San Antonio, Texas · RECRUITING
  • GSK Investigational Site, Wenatchee, Washington · RECRUITING
  • GSK Investigational Site, Madison, Wisconsin · RECRUITING
  • GSK Investigational Site, Heidelberg, Victoria, Australia · RECRUITING
  • GSK Investigational Site, Melbourne, Victoria, Australia · RECRUITING
  • GSK Investigational Site, Bonheiden, Belgium · RECRUITING
  • GSK Investigational Site, Brussels, Belgium · RECRUITING
  • GSK Investigational Site, Leuven, Belgium · RECRUITING
  • GSK Investigational Site, Roeselare, Belgium · RECRUITING
  • GSK Investigational Site, Porto Alegre, Brazil · RECRUITING
  • GSK Investigational Site, São Paulo, Brazil · RECRUITING
  • GSK Investigational Site, Teresina, Brazil · RECRUITING
  • GSK Investigational Site, Calgary, Alberta, Canada · RECRUITING
  • GSK Investigational Site, Toronto, Ontario, Canada · RECRUITING
  • GSK Investigational Site, Montreal, Quebec, Canada · RECRUITING
  • GSK Investigational Site, Sherbrooke, Quebec, Canada · RECRUITING
  • GSK Investigational Site, Helsinki, Finland · RECRUITING
  • GSK Investigational Site, Helsinki, Finland · RECRUITING
  • GSK Investigational Site, Kuopio, Finland · RECRUITING
  • GSK Investigational Site, Tampere, Finland · RECRUITING
  • GSK Investigational Site, Dijon, France · RECRUITING
  • GSK Investigational Site, Marseille, France · RECRUITING
  • GSK Investigational Site, Paris, France · RECRUITING
  • GSK Investigational Site, Paris, France · RECRUITING
  • GSK Investigational Site, Paris, France · RECRUITING
  • GSK Investigational Site, Poitiers, France · RECRUITING
  • GSK Investigational Site, Rennes, France · RECRUITING
  • GSK Investigational Site, Villejuif, France · RECRUITING
  • GSK Investigational Site, Bochum, Germany · RECRUITING
  • GSK Investigational Site, Düsseldorf, Germany · RECRUITING
  • GSK Investigational Site, Frankfurt, Germany · RECRUITING
  • GSK Investigational Site, Lübeck, Germany · RECRUITING
  • GSK Investigational Site, München, Germany · RECRUITING
  • GSK Investigational Site, Milan, Italy · RECRUITING
  • GSK Investigational Site, Milan, Italy · RECRUITING
  • GSK Investigational Site, Pisa, Italy · RECRUITING
  • GSK Investigational Site, Roma, Italy · RECRUITING
  • GSK Investigational Site, Aichi, Japan · RECRUITING
  • GSK Investigational Site, Chiba, Japan · RECRUITING
  • GSK Investigational Site, Hokkaido, Japan · RECRUITING
  • GSK Investigational Site, Osaka, Japan · RECRUITING
  • GSK Investigational Site, Tokyo, Japan · RECRUITING
  • GSK Investigational Site, Tokyo, Japan · RECRUITING
  • GSK Investigational Site, Tuxtla Gutiérrez, Chiapas, Mexico · RECRUITING
  • GSK Investigational Site, Cuernavaca, Morelos, Mexico · RECRUITING
  • GSK Investigational Site, Mexico City, Mexico · RECRUITING
  • GSK Investigational Site, Mexico City, Mexico · RECRUITING
  • GSK Investigational Site, San Pedro Garza García, Mexico · RECRUITING
  • GSK Investigational Site, Amsterdam, Netherlands · RECRUITING
  • GSK Investigational Site, Maastricht, Netherlands · RECRUITING
  • GSK Investigational Site, Rotterdam, Netherlands · RECRUITING
  • GSK Investigational Site, Utrecht, Netherlands · RECRUITING
  • GSK Investigational Site, Lrenskog, Norway · RECRUITING
  • GSK Investigational Site, Oslo, Norway · RECRUITING
  • GSK Investigational Site, Stavanger, Norway · RECRUITING
  • GSK Investigational Site, La Villa de Los Santos, Los Santos Province, Panama · RECRUITING
  • GSK Investigational Site, Punta Pacifica Panama City Panama, Panama · RECRUITING
  • GSK Investigational Site, Brzozów, Poland · RECRUITING
  • GSK Investigational Site, Koszalin, Poland · RECRUITING
  • GSK Investigational Site, Warsaw, Poland · RECRUITING
  • GSK Investigational Site, Seoul, Seoul Teugbyeolsi, South Korea · RECRUITING
  • GSK Investigational Site, Seoul, South Korea · RECRUITING
  • GSK Investigational Site, Seoul, South Korea · RECRUITING
  • GSK Investigational Site, Barcelona, Spain · RECRUITING
  • GSK Investigational Site, HebrOn, Spain · RECRUITING
  • GSK Investigational Site, Madrid, Spain · RECRUITING
  • GSK Investigational Site, Madrid, Spain · RECRUITING
  • GSK Investigational Site, Madrid, Spain · RECRUITING
  • GSK Investigational Site, Pamplona, Spain · RECRUITING
  • GSK Investigational Site, Santander, Spain · RECRUITING
  • GSK Investigational Site, Zaragoza, Spain · RECRUITING
  • GSK Investigational Site, Gothenburg, Sweden · RECRUITING
  • GSK Investigational Site, Lund, Sweden · RECRUITING
  • GSK Investigational Site, Stockholm, Sweden · RECRUITING
  • GSK Investigational Site, Uppsala, Sweden · RECRUITING
  • GSK Investigational Site, Manchester, United Kingdom · RECRUITING

Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors. Registry data refreshed at most hourly; last update posted 2026-08-03.